enVVeno Medical Corporation

NasdaqCM:NVNO Stock Report

Market Cap: US$70.6m

enVVeno Medical Management

Management criteria checks 2/4

enVVeno Medical's CEO is Robert Berman, appointed in Apr 2018, has a tenure of 6.08 years. total yearly compensation is $1.87M, comprised of 26.7% salary and 73.3% bonuses, including company stock and options. directly owns 0.077% of the company’s shares, worth $54.25K. The average tenure of the management team and the board of directors is 6 years and 5.6 years respectively.

Key information

Robert Berman

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage26.7%
CEO tenure6.1yrs
CEO ownership0.08%
Management average tenure6yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Mar 07
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth

Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Aug 14
Will enVVeno Medical (NASDAQ:NVNO) Spend Its Cash Wisely?

Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

Apr 22
Is enVVeno Medical (NASDAQ:NVNO) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Dec 21
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

enVVeno Medical: Unique Exposure To Venous Treatment Domain

Sep 23

We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

Aug 23
We're Hopeful That enVVeno Medical (NASDAQ:NVNO) Will Use Its Cash Wisely

enVVeno Medical reports Q2 results

Aug 03

We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

May 10
We Think enVVeno Medical (NASDAQ:NVNO) Can Afford To Drive Business Growth

We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Jan 25
We're Not Very Worried About enVVeno Medical's (NASDAQ:NVNO) Cash Burn Rate

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 08

Hancock Jaffe Laboratories finance chief sheds interim tag

Dec 31

Hancock Jaffe approves 1:25 reverse stock split

Nov 27

CEO Compensation Analysis

How has Robert Berman's remuneration changed compared to enVVeno Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$500k

-US$24m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$25m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$466kUS$450k

-US$25m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$24m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$10mUS$400k

-US$17m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$1mUS$400k

-US$10m

Sep 30 2020n/an/a

-US$7m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$415kUS$400k

-US$8m

Sep 30 2019n/an/a

-US$7m

Jun 30 2019n/an/a

-US$7m

Mar 31 2019n/an/a

-US$13m

Dec 31 2018US$906kUS$293k

-US$16m

Compensation vs Market: Robert's total compensation ($USD1.87M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


CEO

Robert Berman (60 yo)

6.1yrs

Tenure

US$1,870,884

Compensation

Mr. Robert A. Berman serves as Chief Executive Officer and Director of enVVeno Medical Corporation (formerly known as Hancock Jaffe Laboratories, Inc.) since April 2018. From September 2017 to March 2018,...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director6.1yrsUS$1.87m0.077%
$ 54.3k
Craig Glynn
CFO, Treasurer & Secretary4.1yrsUS$527.29k0%
$ 0
Hamed Alavi
Senior VP & Chief Technology Officer1.3yrsUS$669.19k0%
$ 0
Marc Glickman
Senior VP & Chief Medical Officer8yrsUS$776.38k0.012%
$ 8.5k
Warren Hancock
Co-founder37.3yrsno datano data
Benedict Broennimann
Chief Medical Officer of Outside of United States6yrsUS$240.00kno data
Andrew Cormack
Chief Commercial Officerless than a yearno datano data

6.0yrs

Average Tenure

64yo

Average Age

Experienced Management: NVNO's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Berman
CEO & Director6.1yrsUS$1.87m0.077%
$ 54.3k
Robert Gray
Independent Director4.7yrsUS$77.50k0.057%
$ 40.6k
Matthew Jenusaitis
Independent Director4.7yrsUS$75.00k0.052%
$ 36.7k
Afksendyios Kalangos
Member of Medical Advisory Boardno datano datano data
Francis Duhay
Independent Director5.6yrsUS$70.00k0.16%
$ 110.8k
Steve Elias
Member of Medical Advisory Boardno datano datano data
Antonios Gasparis
Member of Medical Advisory Boardno datano datano data
Wade Dimitri
Member of Medical Advisory Boardno datano datano data
Sanjay Shrivastava
Independent Director5.6yrsUS$75.00k0.029%
$ 20.6k

5.6yrs

Average Tenure

61yo

Average Age

Experienced Board: NVNO's board of directors are considered experienced (5.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.